



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS

March 17, 2020

Dear Healthcare Providers,

In light of the situation with COVID-19, the BC-CfE Laboratory will be temporarily reducing the availability of some of our Precision Medicine tests.

We are also requesting that health care providers limit test requests to only those urgently needed to guide clinical care. Please defer non-essential requests to a later date.

The BC-CfE will continue to perform the following **essential precision medicine tests:**

- Genotypic testing for resistance to HIV Protease Inhibitors, NRTI and NNRTI
- Genotypic testing for resistance to HIV Integrase Inhibitors
- HLA-B*57:01 genotyping for abacavir hypersensitivity reaction

However, the following tests will **not be routinely available until further notice.** Reporting of outstanding requests will likely be delayed. Please contact the BC-CfE lab if results are required urgently.

- HIV gp41 resistance testing for enfuvirtide (T20)
- RNA and proviral DNA-based HIV genotypic co-receptor tropism testing for maraviroc
- Therapeutic Drug Level Monitoring and Untimed Drug Level testing of HIV antiretrovirals
- HCV genotypic drug resistance testing

We will aim to maintain our standard turnaround times as much as possible, however, **delays in reporting may occur.**

We appreciate your understanding and cooperation.

Regards,

Zabrina Brumme, PhD
Laboratory Director
BC Centre for Excellence in HIV/AIDS
604-806-8281
zbrumme@cfenet.ubc.ca

Chanson Brumme, PhD
Assistant Director – Research Laboratories
BC Centre for Excellence in HIV/AIDS
1-800-517-1119
cbrumme@cfenet.ubc.ca